Tisch MS News

We are pleased to announce, Dr. Saud A. Sadiq, Director of the International Multiple Sclerosis Management Practice (IMSMP) and Tisch MS Research Center of New York (Tisch MSRCNY) has been elected a Fellow Member of the American Academy of Neurology (AAN). This outstanding achievement recognizes the contributions Dr. Sadiq has made to the Academy and to the neurology community. To receive this prestigious honor, accomplishments both academically and clinically were taken into consideration.
Your Tisch MS researchers, Dr. Saud A. Sadiq and Dr. Violaine Harris, are presenting this week at the International Society for Stem Cell Research (ISSCR) 12th Annual Meeting. Updates to follow next week.  For more info on the ISSCR and this important event, visit: www.isscr.org 
The Tisch MS research center presented several more posters at the Philadelphia AAN meeting, including: Cerebrospinal Fluid Mononuclear Phagocytes Are Decreased In Number and Express Less IL-10 In Multiple Sclerosis Compared To Values Seen With Normal Controls Shivani Agarwal, Irene Jarchum, Ying Liu, Saud A. Sadiq Summary:
The study summarized in these four slides was selected for a special session at the AAN entitled “Multiple Sclerosis: Highlights in the Field”.  Of the 600+ abstracts submitted to the AAN, 35 were selected to be highlighted in this session as representative of important advances in the field. The presentation was very well received.   AAN slides.pdf
Tuesday, April 29th Today’s Tisch MS Center poster presentations included: Transient Neurologic Worsening after Initiation of Dimethyl Fumarate Therapy in Progressive Multiple Sclerosis Patients James W Stark, Sydney Chirls, Saud Sadiq
By Dr. James W. Stark A study presented at the AAN examined the use of estriol in combination with copaxone in the treatment of 158 relapsing-remitting MS patients. At 12 months, the group treated with both copaxone and estriol had improved relapse rates, however that effect was less apparent at 24 months. The relationship between estrogen and MS is an important area of active study, although the IMSMP does not recommend supplementation for most patients
We are pleased to announce the stem cell research from Tisch MSRCNY has been selected to be presented as a highlight during the Annual Meeting of the American Academy of Neurology. This will take place later today during the portion of the Meeting pertaining to MS. We will provide an update for you tomorrow!
Please read our press release on the success of the Tisch MSRCNY Phase I Clinical Stem Cell Trial campaign on Indiegogo.com.  To continue to support this important initiative CLICK HERE. We are truly grateful to everyone who is helping to fund our mission to repair the damage caused by multiple sclerosis. Indiegogo Goal Reached release.pdf
Tisch MS Research Center of New York is delighted to announce that it has received regulatory approval needed to commence our proposed phase I clinical trial of mesenchymal stem cell-derived neural progenitor cells for the treatment of progressive multiple sclerosis. Patient enrollment and the study will begin shortly.
Tisch MS Research Center of New York continues to be in active deliberation with an Institutional Review Board regarding approval of our stem cell clinical trial. We expect to have all outstanding concerns addressed in the near future and will begin study activities at that time. Please note that IRB approval and FDA approval are separate regulatory matters, and our IRB negotiations do not in any way affect our prior FDA approval. Tisch MS Research Center of New York is committed to full compliance with all laws and regulations concerning the practice of clinical research.


Subscribe to MSRCNY News